Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 8/20 | 0.55 |
| ▸ | MMP2 | P08253 | 4/20 | 0.39 |
| ▸ | MMP9 | P14780 | 3/20 | 0.39 |
| ▸ | MMP8 | P22894 | 3/20 | 0.39 |
| ▸ | MMP13 | P45452 | 3/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | PDE9A | O76083 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2681247 | 0.92 | PDE2A (0.54) | PDE2AMMP2MMP9MMP8MMP13 | |
| SCHEMBL936454 | 0.88 | PDE2A (0.60) | PDE2AMMP2MMP9MMP8MMP13 | |
| SCHEMBL959342 | 0.86 | PDE2A (0.66) | PDE2A | |
| SCHEMBL6883447 | 0.85 | PDE2A (0.54) | PDE2AMMP2MMP9MMP8MMP13 | |
| SCHEMBL935286 | 0.82 | PDE2A (0.54) | PDE2AMMP2MMP9MMP8MMP13 | |
| SCHEMBL6351761 | 0.82 | PDE2A (0.49) | PDE2AMMP2MMP9MMP8MMP13 | |
| SCHEMBL936491 | 0.81 | PDE2A (0.54) | PDE2AMMP2MMP9MMP8MMP13 | |
| SCHEMBL957899 | 0.80 | PDE2A (0.53) | PDE2AMMP2MMP9MMP8MMP13 | |
| SCHEMBL6352137 | 0.80 | PDE2A (0.48) | PDE2AMMP2MMP9MMP8MMP13 | |
| SCHEMBL2680045 | 0.79 | PDE2A (0.64) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2456440-B1 | QUINOLINONE PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2015-08-19 | — | — | EP | claimed |
| US-8680116-B2 | Quinolinone PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-25 | — | — | US | claimed |
| EP-2456440-A1 | QUINOLINONE PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-05-30 | — | — | EP | claimed |
| US-20120115885-A1 | Quinolinone PDE2 Inhibitors | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | claimed |
| WO-2011011312-A1 | QUINOLINONE PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-01-27 | — | — | WO | claimed |
| EP-2456440-B1 | QUINOLINONE PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2015-08-19 | — | — | EP | disclosed |
| EP-2456440-B1 | QUINOLINONE PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2015-08-19 | — | — | EP | disclosed |
| US-8680116-B2 | Quinolinone PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680116-B2 | Quinolinone PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680116-B2 | Quinolinone PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120115885-A1 | Quinolinone PDE2 Inhibitors | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120115885-A1 | Quinolinone PDE2 Inhibitors | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115885-A1 | Quinolinone PDE2 Inhibitors | PDE12, PDE2A, PDE4A | PDE2A 2/4885MMP2 1946/4885MMP9 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.